Health Care [ 4/12 ] | Pharmaceuticals [ 14/72 ]
NASDAQ | Common Stock
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
The company operates through two segments, Human Health and Animal Health.
It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea.
In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs.
The company was founded in 2013 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 21, 24 | -0.07 Increased by +97.07% | -0.03 Decreased by -133.33% |
| Jan 31, 24 | -33.00 Decreased by -862.18% | -73.80 Increased by +55.28% |
| Nov 14, 23 | -0.55 Increased by +93.89% | -1.23 Increased by +55.28% |
| Aug 14, 23 | -0.69 Increased by +92.33% | -1.53 Increased by +54.90% |
| May 15, 23 | -2.39 Increased by +92.04% | -0.04 Decreased by -5.87 K% |
| Mar 27, 23 | -3.43 Increased by +85.25% | -9.75 Increased by +64.82% |
| Nov 14, 22 | -9.00 Increased by +55.56% | -5.62 Decreased by -60.14% |
| Aug 22, 22 | -9.00 Increased by +60.00% | -16.50 Increased by +45.45% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 2.81 M Decreased by -10.70% | -7.78 M Increased by +37.88% | Decreased by -276.50% Increased by +30.43% |
| Jun 30, 23 | 2.68 M Decreased by -8.39% | -12.15 M Decreased by -29.71% | Decreased by -454.04% Decreased by -41.59% |
| Mar 31, 23 | 1.97 M Decreased by -24.88% | -12.20 M Increased by +32.16% | Decreased by -618.76% Increased by +9.69% |
| Dec 31, 22 | 3.26 M Increased by +56.73% | -7.38 M Increased by +48.44% | Decreased by -226.38% Increased by +67.10% |
| Sep 30, 22 | 3.15 M Increased by +400.00% | -12.52 M Decreased by -2.69% | Decreased by -397.46% Increased by +79.46% |
| Jun 30, 22 | 2.92 M Increased by +658.70% | -9.37 M Increased by +33.48% | Decreased by -320.68% Increased by +91.23% |
| Mar 31, 22 | 2.63 M Increased by +111.52% | -17.99 M Decreased by -49.77% | Decreased by -685.18% Increased by +29.19% |
| Dec 31, 21 | 2.08 M Decreased by -19.25% | -14.31 M Decreased by -63.22% | Decreased by -688.13% Decreased by -102.15% |